Nov. 28, 2012
/PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced it will present both SURFAXIN
data at the 2012 Hot Topics in Neonatology Annual Meeting being held
in Washington D.C. Hot Topics in Neonatology is an internationally recognized medical meeting dedicated to advancing the practice of neonatology.
Earlier this year, SURFAXIN became the first Food and Drug Administration (FDA)-approved synthetic, peptide-containing surfactant for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk of developing RDS. Also, in
, the company's AFECTAIR device was registered with the FDA and cleared for marketing in the United States. AFECTAIR is a proprietary disposable airway connector that simplifies the delivery of aerosolized medications to critical-care patients requiring ventilatory support from either intermittent mechanical ventilation or continuous positive airway pressure.
Discovery Labs presentations at Hot Topics in Neonatology include:
- Pharmacoeconomic Impact of Bronchopulmonary Dysplasia in Reintubated Infants – Simmons PD and Clayton RG
- In Vitro Comparison of Albuterol Delivery Using a Novel Neonatal Ventilator Circuit Connector with Three Different Neonatal Ventilators – Gregory TJ, Henderson C, Mazela J, Boppana V, and Clayton RG
Additionally, a late-breaker platform presentation entitled
New insights into effective aerosol therapy in premature infants - Are we ready to inhale surfactants?
will provide a comprehensive review of aerosolized treatment options for RDS today and into the future. This topic, which is relevant to Discovery Labs' aerosolized KL
surfactant development candidate, AEROSURF
will be presented at
For over 30 years, Hot Topics has been the premier neonatal conference, with more than 1,000 neonatologists and perinatologists attending each year. For more information about Discovery Labs and its products, attendees can visit Discovery Labs in the Hot Topics in Neonatology Internet Café or visit
IMPORTANT SAFETY INFORMATION
SURFAXIN (lucinactant) Intratracheal Suspension is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly-supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.
Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized. SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).